ArticleClinical and experimental medicine2026
NF1/2 mutations predict favorable benefit from immune checkpoint inhibitor-based therapies over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma.
Yi Sun et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.